



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Emilio Perucca**

Organisation/Company: University of Melbourne

Country: Australia

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/1995-06/2021	UCB Pharma	Levetiracetam, brivaracetam, lacosamide, padsevonil and other potential antiepileptics	epilepsy
01/2006-(current)	Eisai	zonisamide, rufinamide, eslicarbazepine acetate, perampanel	epilepsy
05/2014-05/2021	GW Pharma	cannabinoids	epilepsy
11/2021-(current)	SK Life Science, Inc.	antiseizure compounds	epilepsy
11/2021-(current)	Biogen	antiepilepsy compounds	epilepsy
07/2021-(current)	Angelini	cenobamate	epilepsy
01/2021-07/2021	Zogenix	Fenfluramine	Epilepsy
11/2021-(current)	Takeda	Soticlestat	Epilepsy
11/2021-(current)	Sanofi	valproate	epilepsy

Classified as public by the European Medicines Agency

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
01/1995-12/2020	UCB Pharma	padsevonil, levetiracetam, brivaracetam	epilepsy
01/2000-11/2021	Eisai	perampanel	epilepsy
10/2019-01/2020	Lundbeck	anticonvulsants	epilepsy
01/2015-(current)	Takeda	antiepilepsy compounds	epilepsy
05/2014-12/2020	GW Pharma	cannabinoids	epilepsy
11/2018-12/2020	Biogen	CNS drug development with special reference to epilepsy drugs	
06/2019-08/2021	Arvelle	cenobamate	epilepsy
05/2018-(current)	Xenon Pharma	anticonvulsants	epilepsy
05/2019-12/2020	Corlieve	epilepsy treatments	
11/2020-06/2021	Zogenix	fenfluramine	epilepsy
10/2020-05/2021	Sanofi	Valproate	Epilepsy
11/2021-(current)	SK Life Sciences Inc	Antiepilepsy compound	Epilepsy
06/2022-(current)	Shackelford Pharma	THC	epilepsy
07/2022-(current)	Grin Therapeutics	neurodevelopmental and related disorders	
10/2021-(current)	Janssen	epilepsy products	epilepsy

2.4 Financial interests

Company	Financial Interest
Sanofi	Consultant
UCB Pharma	Speaker, consultant
Eisai	Speaker, consultant
GW Pharma	Speaker, consultant
Biogen	Consultant
Xenon Pharma	Advisory Board
Zogenix	Consultant, editorial activities, speaker
Angelini	Consultant, Advisory Board, Speaker
Janssen Pharmaceutica	Advisory Board
SK Life Sciences, Inc.	Consultant, Advisory Board
Takeda	Consultant, . Advisory Board
Shackelford Pharma	Advisory Board
Grin Therapeutics	Advisory Board
Sun Pharma	Editorial activities

Classified as public by the European Medicines Agency

3

2.5 Principal investigator

No interest declared

2.6 Investigator

No Interest Declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

I am a member of the Executive Board of the International League against Epilepsy (ILAE), which produces documents /publications which can be relevant for drug development and utilization of epilepsy medicines.

I am a member of the Steering Committee of the ERN EpiCARE, which deals with diagnosis and management of rare and complex epilepsies.

I am in the Board of Directors of European Alliance Europe (an advocacy organization which relates to ILAE and to the International Bureau for Epilepsy), of the ILAE Secretariat (a company which serves ILAE-related function), and of the ROW Foundation (a non profit U.S. organization which supplies epilepsy medications free of charge) to communities in need. I receive neither direct or indirect compensation for all of those roles.

I also work in a large academic organization (Department of Internal Medicine and Therapeutics, University of Pavia, Italy) and my colleagues may provide consultancy services to pharma and device industries which I am not personally involved with.

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in

Classified as public by the European Medicines Agency

EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	EMILIO PERUCCA
Date:	2022-10-10

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template